The ICP - Innovators Commercialisation Program is led by Asia Research & Innovation Alliance (ARIA)'s Institute of Healthtech Excellence, in collaboration with the National University Hospital of Singapore (NUHS) - Centre for Innovation in Healthcare (CIH). ICP program helps innovators to accelerate their product validation and expansion into Singapore. A global team of healthcare professionals and clinicians will offer clinical validation and venture building support to grow your business in Singapore and the region over a 6 months program. Completion of the ICP program will allow innovators access to venture investment of up to USD1,000,000. BENEFITS OF THE PROGRAM - Venture Funding of $1million Dollars - Establish Global HQ in Singapore with Regulatory Incentives - Fast Track to Clinical Adoption and Trials in Singapore and across Asia - Network with the largest Medtech companies in the world - Access to a Global Committee of Medical Industry Professionals PROGRAM THEMES 1. Improving Users Lifespans and Quality of Life 2. Enabling Seamless Delivery of High-Quality Healthcare 3. Digitalisation of Hospital Systems 4. Enhancing Women's and Children's Health Outcomes PROGRAM STRUCTURE The program is split into 3 phases of 6 months in total: 1. Phase 1 covers the Clinical Validation phase with the NUHS-CIH team, with access to 3 major hospitals and 8 polyclinics in Singapore. 2. Phase 2 is the product actuation process with the venture building team comprising of top medical industry professionals. 3. Phase 3 is the venture funding and scale-up process, with key support provided in operational roles SELECTION CRITERIA 1. Prototypes have been developed 2. Patents approved or pending approval 3. Obtained preliminary clinical trial data and/or published in research publications 4. Business plans developed HOW DO YOU APPLY? Send your 1 slide business plan to connect@ariainstitute.org OR apply through the website https://www.ariainstitute.org/icp